Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gal Medalia"'
Autor:
Baruch Brenner, Michal Sarfaty, Ofer Purim, Yulia Kundel, Limor Amit, Amir Abramovich, Udi Sadeh Gonik, Efraim Idelevich, Noa Gordon, Gal Medalia, Aaron Sulkes
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0157548 (2016)
Current treatment options for advanced esophagogastric cancer (AEGC) are still unsatisfactory. The aim of this prospective phase Ib/II study was to evaluate the safety and efficacy of a novel regimen, AVDCX, consisting of weekly docetaxel and cisplat
Externí odkaz:
https://doaj.org/article/88de818c807e42978bce4763baaf7652
Autor:
Amir Abramovich, Efraim Idelevich, Gal Medalia, Baruch Brenner, Ofer Purim, Noa Gordon, Yulia Kundel, Aaron Sulkes, Limor Amit, Udi Sadeh Gonik, Michal Sarfaty
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 7, p e0157548 (2016)
PLoS ONE, Vol 11, Iss 7, p e0157548 (2016)
Introduction Current treatment options for advanced esophagogastric cancer (AEGC) are still unsatisfactory. The aim of this prospective phase Ib/II study was to evaluate the safety and efficacy of a novel regimen, AVDCX, consisting of weekly docetaxe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94e64c4acb63313ae1140490c9ad85e4
https://pubmed.ncbi.nlm.nih.gov/27390847
https://pubmed.ncbi.nlm.nih.gov/27390847
Autor:
Eli Rosenbaum, Riva Kovjazin, Ilan Volovitz, Lior Carmon, Baruch Brenner, Yulia Kundel, Gal Medalia, Galit Horn, Nechama I. Smorodinsky
Publikováno v:
Vaccine. 29(29-30)
An optimal cancer vaccine should be able to induce highly potent, long-lasting, tumor-specific responses in the majority of the cancer patient population. One approach for achieving this is to use synthetic peptide vaccines derived from widely expres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b656805d52c855a866eb917676188b94
https://pubmed.ncbi.nlm.nih.gov/21570434
https://pubmed.ncbi.nlm.nih.gov/21570434
CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
Autor:
Pnina Fishman, Ofer Benjaminov, William D Kerns, Barak Singer, Salomon M. Stemmer, Motti Farbstein, Renana Petoka, Sara Bar Yehuda, Noa Beatrice Ciuraru, Gal Medalia, Sari Fishman, Shira Cohen, Zivit Harpaz, Michael H Silverman
Publikováno v:
The Oncologist. 18:25-26
Background. The A3 adenosine receptor (A3AR) is overexpressed in the tumor and in the peripheral blood mononuclear cells of patients with hepatocellular carcinoma (HCC). The orally active drug candidate CF102, an A3AR agonist, induces apoptosis of HC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7e032a8fc2d066c3849ebdbeb9fea59
https://doi.org/10.1634/theoncologist.2012-0211
https://doi.org/10.1634/theoncologist.2012-0211
Autor:
Udi Sadeh Gonik, Baruch Brenner, Ofer Purim, Yulia Kundel, Aaron Sulkes, Noa Gordon, Efraim Idelevich, Gal Medalia
Publikováno v:
Journal of Clinical Oncology. 31:e15078-e15078
e15078 Background: Many efforts are being made to improve treatment options for advanced esophagogastric cancer (AEGC). The aim of this phase Ib/II study was to evaluate the safety and efficacy of a novel regimen, AVDCX, consisting of weekly docetaxe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38f8ec6a846b1ff9041dc928f39f30cb
https://doi.org/10.1200/jco.2013.31.15_suppl.e15078
https://doi.org/10.1200/jco.2013.31.15_suppl.e15078
Autor:
Baruch Brenner, Hanoch Kashtan, Eyal Fenig, Gal Medalia, Ofer Purim, Nikolai Menasherov, Yulia Kundel, Liran Olshinka, Aaron Sulkes, Efraim Idelevich
Publikováno v:
Journal of Clinical Oncology. 30:e14571-e14571
e14571 Background: This prospective phase IB/II study evaluated the safety and efficacy of the addition of cetuximab to standard preoperative chemoradiation (CRT) in locally advanced esophageal cancer (LAEC). We hereby report its preliminary results.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c30ff0790138faaf35db67cb6ba4080f
https://doi.org/10.1200/jco.2012.30.15_suppl.e14571
https://doi.org/10.1200/jco.2012.30.15_suppl.e14571
Autor:
O. Binyaminov, P. Fishman, Zivit Harpaz, Sari Fishman, Salomon M. Stemmer, William D Kerns, Michael H. Silverman, Gal Medalia, S. Bar Yehuda, Motti Farbstein
Publikováno v:
European Journal of Cancer Supplements. 8:122
Methods: The objectives of this trial are to evaluate the safety and pharmacokinetic (PK) behavior of CF102 in HCC patients. Utilizing a “3+3” design, successive cohorts of patients with advanced HCC were enrolled at CF 102 doses of 1, 5, or 25 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a4afbdfdcfdf480226f1e30c222686c
https://doi.org/10.1016/s1359-6349(10)72091-7
https://doi.org/10.1016/s1359-6349(10)72091-7